BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33400854)

  • 1. Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase.
    Talibov VO; Fabini E; FitzGerald EA; Tedesco D; Cederfeldt D; Talu MJ; Rachman MM; Mihalic F; Manoni E; Naldi M; Sanese P; Forte G; Lepore Signorile M; Barril X; Simone C; Bartolini M; Dobritzsch D; Del Rio A; Danielson UH
    Chembiochem; 2021 May; 22(9):1597-1608. PubMed ID: 33400854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus NS5A protein interacts with lysine methyltransferase SET and MYND domain-containing 3 and induces activator protein 1 activation.
    Chen M; Gan X; Yoshino K; Kitakawa M; Shoji I; Deng L; Hotta H
    Microbiol Immunol; 2016 Jun; 60(6):407-17. PubMed ID: 27080060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
    Brown MA; Foreman K; Harriss J; Das C; Zhu L; Edwards M; Shaaban S; Tucker H
    Oncotarget; 2015 Feb; 6(6):4005-19. PubMed ID: 25738358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
    Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
    Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
    Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
    Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
    Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
    Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
    Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
    Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
    Sun J; Li Z; Yang N
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
    Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
    SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
    Xu S; Wu J; Sun B; Zhong C; Ding J
    Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.
    Hayashi M; Deng L; Chen M; Gan X; Shinozaki K; Shoji I; Hotta H
    Microbiol Immunol; 2016 Jan; 60(1):17-25. PubMed ID: 26616333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
    Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
    Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
    Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
    J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
    Parenti MD; Naldi M; Manoni E; Fabini E; Cederfelt D; Talibov VO; Gressani V; Guven U; Grossi V; Fasano C; Sanese P; De Marco K; Shtil AA; Kurkin AV; Altieri A; Danielson UH; Caretti G; Simone C; Varchi G; Bartolini M; Del Rio A
    Eur J Med Chem; 2022 Dec; 243():114683. PubMed ID: 36116234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
    Kim H; Heo K; Kim JH; Kim K; Choi J; An W
    J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
    Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
    Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
    Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
    IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand Binding, Unbinding, and Allosteric Effects: Deciphering Small-Molecule Modulation of HSP90.
    D'Annessa I; Raniolo S; Limongelli V; Di Marino D; Colombo G
    J Chem Theory Comput; 2019 Nov; 15(11):6368-6381. PubMed ID: 31538783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
    Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.